Synthesis and Pharmacokinetics of Valopicitabine (NM283), an Efficient Prodrug of the Potent Anti-HCV Agent 2‘-C-Methylcytidine
摘要:
In our search for new therapeutic agents against chronic hepatitis C, a ribonucleoside analogue, 2'-C-methylcytidine, was discovered to be a potent and selective inhibitor in cell culture of a number of RNA viruses, including the pestivirus bovine viral diarrhea virus, a surrogate model for hepatitis C virus (HCV), and three flaviviruses, namely, yellow fever virus, West Nile virus, and dengue-2 virus. However, pharmacokinetic studies revealed that 2'-C-methylcytidine suffers from a low oral bioavailability. To overcome this limitation, we have synthesized the 3'-O-L-valinyl ester derivative (dihydrochloride form, valopicitabine, NM283) of 2'-C-methylcytidine. We detail herein for the first time the chemical synthesis and physicochemical characteristics of this anti-HCV prodrug candidate, as well as a comparative study of its pharmacokinetic parameters with those of its parent nucleoside analogue, 2'-C-methylcytidine.
NM 283, AN EFFICIENT PRODRUG OF THE POTENT ANTI-HCV AGENT 2′-C-METHYLCYTIDINE
摘要:
In order to improve the oral bioavailability of 2'-C-methylcytidine, a potent anti-HCV agent, the corresponding 3'-O-L-valinyl ester derivative (NM 283) has been synthesized. Based on its ease Of synthesis and its physicochemical properties, NM 283 has emerged as a promising antiviral drug for treatment of chronic HCV infection.
[EN] PROCESS FOR THE PRODUCTION OF 3'-NUCLEOSIDE PRODRUGS<br/>[FR] PROCEDE DE PRODUCTION DE PROMEDICAMENTS A BASE DE 3'-NUCLEOSIDES
申请人:IDENIX CAYMAN LTD
公开号:WO2004058792A1
公开(公告)日:2004-07-15
Provided is a single-step process for the selective 3'-acylation of a ribofuranosyl 2' or 3'-branched nucleoside. These compounds are useful as antiviral agents, and in particular,can be used to treat Flaviviridae infections in a host in need t hereof.